CovidVax show full list
COVID-19 VACCINE:

replication defective simian adenovirus

researcher:
ReiThera + Leukocare + Univercells
https://www.reithera.com/
https://www.leukocare.com/start.html
https://www.univercells.com/
(Italy + Germany + Belgium)
vaccine type: Non-replicating viral vector
Distribution updates
May 14Univercells will partner with Exyte to optimize construction of modular manufacturing facilities (by univercells.com)
Human Testing updates (clinical trials)

PHASE 1

 

started August 10 2020

with 90 healthy volunteers aged 18+

trial location: Italy

» clinical trial details

Nov 24ReiThera said its vaccine is well tollerated and induces immune responses in healthy subjects aged 18-55 (by reithera.com)
Aug 24ReiThera announced today that the first healthy volunteer has been dosed with the vaccine (by reithera.com)
Jul 31Reithera will soon start testing its vaccine in Italy on 90 healthy individuals to evaluate its safety (by corriere.it)
Jul 31GRAd-COV2's Phase 1 trial will enroll 90 people split in two cohorts of 45 people each (by aifa.gov.it)
Apr 23ReiTheraLeukocare's vaccine candidate is expected to enter clinical trials during summer 2020 (by prnewswire.com)
Animal Testing updates (pre-clinical trials)
start date: June 2020
Jul 03GRAd-COV2 is currently in preclinical trials evaluating immune responses and efficacy (by covidx.eu)
early development updates
currently no early development info



partnerships:
Apr 24ReiThera Leukocare and Univercells will collaborate to develop and manufacture a vaccine (by genengnews.com)



contact | about | ©2020 CovidVax.org project